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ABSTRACT
Introduction Age- related macular degeneration (AMD) 
is a common cause of visual impairment, affecting 
central vision. Geographic atrophy (GA) is an advanced 
form of the non- neovascular (dry) type of AMD. Late- 
stage clinical trials suggest that intravitreal injections 
of novel therapeutics may slow down the rate of GA 
progression by up to 30% in 1 year, thus allowing 
people with GA to preserve central vision for a longer 
period. While intravitreal injections have become an 
established treatment modality for neovascular (wet) 
AMD, it is unknown whether patients with (more gradually 
progressing) GA would accept regular injections that slow 
down, but do not stop or reverse, vision loss. Therefore, 
this mixed- methods pilot study will aim to explore whether 
regular intravitreal injections will be acceptable as 
treatment for patients with GA, and the factors that may 
affect treatment acceptability.
Methods and analysis A mixed- methods survey 
has been designed in collaboration with a GA patient 
advisory group. The survey comprises of structured 
questionnaires, semi- structured interview questions 
regarding patients’ perceptions of intravitreal injections 
and the burden of treatment, and a task eliciting 
preferences between different potential treatments. Due 
to COVID-19 restrictions, this study will be conducted 
remotely by telephone. Thirty individuals will be recruited 
from NHS Medical Retina clinics at Central Middlesex 
Hospital, London. Half of the participants will be naïve 
to intravitreal injections, while half will have previous 
experience of intravitreal injections for neovascular (wet) 
AMD. Qualitative data analysis will be conducted using the 
Framework Method of analysis to identify key themes from 
participants’ accounts.
Ethics and dissemination The study received Health 
Research Authority approval on 23 March 2021 (IRAS 
Project ID: 287824). Findings will be disseminated through 
peer- reviewed publications and conference presentations 
to the medical retina community, as well as through 
dialogue with patients and macular disease charities.
INTRODUCTION
Age- related macular degeneration (AMD) is 
the most common cause of sight loss in devel-
oped countries.1 Sight loss from advanced 
AMD occurs either as neovascular or ‘wet’ 
age- related macular degeneration (nAMD) 
or geographic atrophy (GA). In the UK, GA 
is estimated to account for one quarter of 
legal blindness, and globally approximately 
5 million people have GA in at least one eye.2 
Patients with GA generally develop retinal 
lesions which can lead to irreversible vision 
loss, and about half of patients develop GA in 
both eyes within 7 years of initial diagnosis.3
There is currently no therapy for GA, 
although researchers are making significant 
progress in understanding and developing 
potential treatments that may slow down the 
growth of GA lesions. These include oral 
treatments such as ALK-001 and doxycy-
cline,4 5 and surgical delivery of gene therapy 
in phase II trials.6 Showing promising results 
and now in late stage clinical trials are drugs 
Strengths and limitations of this study
 ► This is the first study to investigate the acceptabili-
ty of emerging geographic atrophy (GA) treatments 
for patients living with the condition. The resulting 
findings will help to understand the psychosocial, 
demographic and health service factors that may 
influence treatment acceptability.
 ► All aspects of the study are benefiting from the input 
of an advisory group, eight individuals living with GA 
who are helping to shape the study design, analysis 
and dissemination.
 ► Following analysis, findings from this pilot study will 
be used as the basis for a subsequent quantitative 
study, where we will recruit a larger sample of pa-
tients with GA from a range of sites across the UK.
 ► Due to the COVID-19 pandemic, this pilot study will 
be conducted remotely. While we have engaged an 
advisory group of patients living with GA to help us 
develop the study in this format, there is a risk of 
losing non- verbal information during interviews 
conducted remotely.
 ► Taking a qualitatively driven mixed- methods ap-
proach means that we will be conducting in- depth 
interviews with a small number of participants from 
one eye clinic, which limits the generalisability of the 
study findings.
 on M









pen: first published as 10.1136/bm





2 Enoch J, et al. BMJ Open 2021;11:e049495. doi:10.1136/bmjopen-2021-049495
Open access 
targeting the complement cascade and neuroprotective 
drugs. These are delivered by injection into the patient’s 
eye, known as intravitreal injections. Table 1 describes 
intravitreal treatments that have been or are currently 
being evaluated in phase III clinical trials.
Intravitreal injections are delivered into the patient’s 
eye at regular intervals for an indefinite period, as is 
currently standard practice for nAMD. The current 
treatments under investigation are delivered at monthly, 
bimonthly or 3 monthly intervals and have been shown 
to slow down GA lesion growth by up to 30% in 1 year, 
depending on the therapy and how often injections are 
delivered (table 1).7 This would translate to lesions taking 
longer to affect central vision and patients therefore 
keeping useful central vision for a longer period.
Learning lessons from treatment of nAMD
Regular intravitreal injections of anti- vascular endothe-
lial growth factor (anti- VEGF) are used extensively in 
treatment of nAMD to slow or halt disease progression. 
Anti- VEGF injections have substantially reduced the prev-
alence of sight loss attributable to nAMD.8
However, studies of patients receiving intravitreal injec-
tions for nAMD show evidence of significant anxiety, 
stress, discomfort and pain associated with these injec-
tions.9–12 A recent metasynthesis of qualitative research 
on experiences of patients with nAMD summarises poten-
tial negative impacts of repeated injections:
The time spent at clinics, the injection itself, over-
crowded ophthalmic practices and hospitals, the 
number of examinations, communication problems 
with medical staff, information deficits and the side 
effects of treatment are often debilitating and nerve- 
wracking for many patients.13
Patients also often express concern about the burden 
on relatives and carers who may transport or accom-
pany them to hospital for these appointments.10 Indeed, 
a recent Macular Society survey found that 61.6% of 
patients receiving anti- VEGF treatment rely on friends 
or family to take them to and from eye clinic appoint-
ments.14 A complex interaction of patient- related 
health, demographic, psychological, socioeconomic and 
geographical factors may combine with characteristics 
of the treatment delivery and health system and create 
barriers to adhering and persisting with treatment (see 
figure 1).15 16 The nAMD literature suggests that loss to 
follow- up after initiating treatments is highest in the first 
year.16–18 Many determinants of non- adherence/non- 
persistence in patients treated with intravitreal injections 
for nAMD are unmodifiable, such as age, visual acuity 
and ocular or systemic comorbidities when commencing 
treatment. However, other key barriers—such as distance 
from the hospital,17 18 travel times and transportation 
implications19—could be addressed by improving health 
service delivery, with some small studies suggesting that 
‘one- stop’ style services combining monitoring and injec-
tions could improve adherence.20 21
Nonetheless, despite high treatment burden, the possi-
bility of further sight loss from nAMD has often been 
found to outweigh negative experiences and to motivate 
patients to continue treatment.10 22 23 In a discrete choice 
experiment study, desire to prevent deterioration of 
visual acuity was by far the most significant factor in treat-
ment decision- making, in nearly three- quarters of cases.24 
Table 1 Summary of investigational intravitreal treatments for GA
Name of drug
Trial name (ClinicalTrials.gov 
identifier) Interim or published results
APL-2 FILLY (NCT02503332)
DERBY and OAKS (NCT03525600 and 
NCT03525613)
In a phase II trial, APL-2 administered monthly via 
intravitreal injection showed a 29% statistically significant 
reduction in the rate of GA lesion growth compared with 
sham after 12 months of treatment.36
Two phase III multicentre trials are underway.
Zimura (avacincaptad 
pegol)
GATHER1 phase II/III trial 
(NCT02686658)
GATHER2 phase III trial 
(NCT04435366)
In a phase II/III trial, avacincaptad pegol administered 
monthly via intravitreal injection significantly reduced 
GA growth over 12 months by 27.4% (2 mg cohort) and 
27.8% (4 mg cohort) compared with sham.37
Brimonidine (Brimo DSS) BEACON (NCT02087085) In a phase IIb study, Brimo DDS administered every 
3 months via intravitreal injection significantly decreased 




No statistically significant improvements. In phase III 
trials, patients with bilateral GA experienced a consistent 
decline in visual function over 48 weeks. Measures of 
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Even while anxiety about injections may be common, this 
is often outweighed by anxieties regarding vision loss or 
the treatment’s failure to work effectively.18
In contrast to nAMD, where loss of vision is typically 
sudden and treatment leads to improvements in vision, 
disease progression and vision loss in GA is a gradual 
process. Moreover, current intravitreal treatments in 
late phase development for GA (shown in table 1) slow 
down the rate of vision loss, but do not stop or reverse 
vision loss. It is therefore not yet known whether patients 
with GA will be similarly motivated to adhere to frequent 
intravitreal treatments, how often they would be willing 
to undergo them and what factors would make such treat-
ments acceptable to patients with GA. Therefore, it is vital 
to explore how patients with GA themselves perceive the 
anticipated benefits and drawbacks of these treatments, 
and consider their overall acceptability.
A theoretical framework of acceptability
For the purposes of this protocol and the pilot study, we 
define acceptability in accordance with Sekhon, Cart-
wright and Francis’ comprehensive review as:
A multi- faceted construct that reflects the extent to 
which people delivering or receiving a healthcare 
intervention consider it to be appropriate, based on 
anticipated or experienced cognitive and emotional 
responses to the intervention.25
In table 2, we consider the seven components of 
Sekhon et al’s theoretical framework of acceptability, with 
concrete examples in the context of our study.
Living with GA: the patient experience
While treatment acceptability for GA is a novel research 
area, it is also worth noting the very limited research 
on patient experiences of living with dry AMD and with 
GA in particular, when compared with nAMD.26 The 
small number of studies in this field have documented 
anxieties around progression of dry AMD and GA, 
hopelessness and despair regarding the lack of treat-
ment options, and fears for a future with more limited 
sight and greater dependence on others.27–29 A partic-
ular concern which participants have raised in qualita-
tive studies is the very limited provision of information 
or advice at the point of diagnosis, beyond being told 
that nothing can be done for the condition. The lack 
of information, or the unclear and inaccessible nature 
of available information, may compound the sense of 
confusion and frustration many individuals living with 
the condition may feel. Therefore, in light of limited 
research on the impact of GA on patients’ quality of life, 
we will explore patients’ understanding and experience 
of their condition alongside the core theme of treat-
ment acceptability.
We will use semi- structured interviews, designed with 
patient input to explore themes around patient perspec-
tives on GA progression and current treatment options, 
the impact of GA on their quality of life, and their percep-
tions of the acceptability of intravitreal injections and 
associated burdens. Particular attention will be placed 
on patients’ perceptions of GA treatments which (unlike 
nAMD treatments) will not reverse or stop vision loss, but 
only slow down the rate of vision loss.
Study objectives
Our objectives are to explore the following research 
questions:
 ► How acceptable are regular eye injections to people 
with GA?
 ► What are the factors that would affect acceptability of 
regular eye injections for people with GA?
 ► What is the level of treatment burden that patients 
with GA will accept in order to slow further visual 
decline?
Figure 1 Summary of factors that may affect acceptability of intravitreal treatments, based on the neovascular age- related 
macular degeneration literature.16 58 59
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 ► How do people with GA understand and perceive 




This is a mixed- methods cross- sectional study, which will 
start in April 2021. At the time of writing, the COVID-19 
pandemic and associated restrictions have had profound 
medical and social repercussions for older adults in 
particular (the group most at risk of GA). It is important 
to continue to involve older adults in non- COVID- related 
research while minimising risk and in line with govern-
ment guidelines.30 As such, the decision was made to 
conduct the research remotely, following discussion with 
our patient advisory group. Conducting the study by tele-
phone, as opposed to videoconferencing, was considered 
the most accessible and appropriate medium in order to 
standardise the procedure and to avoid digital exclusion 
of certain participants.31 32
Telephone interviews will be arranged at a time conve-
nient for participants, and will last approximately 90 min. 
Interviews will be audio recorded with participants’ 
consent. In addition, participant responses to multiple 
choice or Likert- type scale questions will be inputted into 
Qualtrics, with responses delinked from any personal 
identifiable information.
The interview flow is displayed in figure 2, and the eight 
interview components are explained in turn below.
Sociodemographic questions
Participants will be asked basic questions regarding socio-
demographic factors, including age, ethnicity, primary 
language, highest education level and employment status. 
This section will also ask about participants’ living situa-
tion, whether a relative or caregiver normally accompa-
nies them to hospital appointments, and time taken and 
mode of transport to travel to hospital appointments.
Patient-reported outcome measure: the EQ-5D-5L
We will verbally administer the five level EQ- 5D 
(EQ- 5D- 5L), which provides a standardised measure of 
participants’ generic health state across five dimensions: 
mobility, self- care, usual activities, pain/discomfort and 
anxiety/depression.33
Structured questions about knowledge and concerns regarding GA
We will ask Likert- type scale questions to gauge partici-
pants’ knowledge about their GA, and how they perceive 
its severity and likely progression.
Table 2 The seven component constructs in Sekhon et al’s theoretical framework of acceptability (TFA),25 and how these 
could apply to intravitreal treatment for GA
Component 
construct in TFA Definition within the TFA Example with potential relevance to GA treatment
Affective attitude How an individual feels about the 
intervention
Anxiety about the injection, despair and fear of losing vision, 
or hope of slowing vision loss.
Burden The perceived amount of effort that is 
required to participate in the intervention
The challenges of monthly visits to clinic for injections, 
eg, associated pain and discomfort, transport issues, or 
potential impact on accompanying relatives.
Ethicality The extent to which the intervention has a 
good fit with an individual’s value system
Some individuals with GA may be more proactive and feel 
they can take control by having injections. Meanwhile, other 
individuals could be more fatalistic (or accepting) about the 
inevitability of vision loss, especially if treatment outcomes 
are unclear or uncertain.60 Our patient advisors also 
highlighted that some people with GA may have concerns 




The extent to which the participant 
understands the intervention and how it 
works; the face validity of the intervention 
for the recipient
Clear understanding of the impact the intravitreal injections 
would have, in terms of slowing down the rate of vision loss 
from GA (rather than halting or reversing it).
Opportunity costs The extent to which benefits, profits or 
values must be given up to engage in the 
intervention
If a person with GA (and/or an accompanying relative/




The extent to which the intervention is 
perceived as likely to achieve its purpose
An appreciable sense that the intravitreal injections are 
slowing the patient’s rate of vision loss.
Self- efficacy The participant’s confidence that they 
can perform the behaviour required to 
participate in the intervention
Confidence in ability to attend regular injections and to 
persist with treatment over the long term.
GA, geographic atrophy; NHS, National Health Service.
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Delivery of information about treatment options
At this point, we will provide participants with brief infor-
mation about interim findings of clinical trials of GA treat-
ments under investigation (see table 1). The interviewer 
will explain that treatments have been found to be safe 
and slow down the rate of progression of GA by up to 30%. 
A concrete example will be provided in terms of how the 
injections will help preserve functional vision for up to 
30% longer compared with no treatment, since compari-
sons framed in absolute rather than percentage terms are 
generally more easily understood.34 35 As suggested by our 
patient advisory group, we will also include information 
on potential risks and burden of treatment, including 
side effects, pain and discomfort, potential risk of devel-
oping nAMD,36 37 and anxiety that intravitreal injections 
may cause. Participants will be invited to ask questions 
and the interviewer will clarify aspects of the information.
Structured questions to assess thoughts on the treatment options
Participants will be asked brief three- point and five- point 
Likert- type scale questions to gauge their views on the 
benefits versus risks of the treatments described. They 
will be asked if they would be willing to have injections 
at different time intervals (each month, every 2 months, 
every 3 months or every 6 months).
Semi-structured questions about treatment options
Participants will then be asked a series of open- ended 
questions to explore their thoughts on advantages and 
disadvantages of the various treatment options, and 
barriers and facilitators of committing to treatment. 
While questions can be adapted depending on partici-
pants’ responses and central concerns, a core set of ques-
tions will explore how participants evaluate the probable 
benefits of treatment against the burden, opportunity 
costs and risks of treatment. Participants will be invited to 
discuss how the treatment process would impact not only 
them but also relatives, friends and caregivers in their life, 
including those who may accompany them to hospital 
appointments. We will also ask for participants’ views on 
support and information that could help with decision- 
making and coping with challenges of treatment. If the 
participants have experience of intravitreal injections for 
any indication, they will also be asked to elaborate on 
their experiences of receiving these.
Participants will be deliberately encouraged to say as 
much as they can in response to the questions. The inter-
viewers will provide prompts to encourage participants to 
share their views, while taking special care to avoid saying 
anything detailed that could be interpreted as leading or 
coercive.
Discrete choice experiment (DCE)-style task
In a DCE, participants are presented with two or more 
alternative products or scenarios, and asked to choose 
which they believe would be most appropriate. A true 
DCE would typically be administered to a larger number 
of participants (based on a sample size calculation), with 
the attributes of interest (eg, frequency of injection) and 
various levels (eg, once per month, once every 2 months 
and so on) computer- randomised to compile different 
choice sets.38 39
In contrast, in our pilot exploratory study, we will 
ask participants to directly compare four hypothetical 
scenarios of different treatments and outcomes, presented 
in pairs in random order, to assess patient preferences for 
treatment options. One option is a ‘No treatment’ option, 
while the other three options are based on the treatment 
attributes of APL-2, Brimonidine and Zimura.
Based on feedback from our patient advisory group, 
we are not asking participants to choose between treat-
ment options for themselves, in order to avoid confusion 
when the option may not be relevant to them (eg, if they 
themselves would not benefit from treatment due to the 
advanced stage of their GA). Instead, we will ask them 
to compare different treatment options for an imagi-
nary patient. We will subsequently ask participants which 
option they would choose after weighing up advantages 
and disadvantages. We will acknowledge that they may 
not necessarily recommend either option, but for the 
Figure 2 Summary of overall study procedure. GA, 
geographic atrophy.
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purposes of this exercise, they should select one of the 
two options.
Participants will be asked to ‘think out loud’ and 
explain their decisions in as much detail as possible. This 
technique has been used to generate qualitative data 
from a DCE exploring patient preferences for nAMD 
treatment40; the collection of qualitative data within a 
DCE task can help detect and resolve participant misun-
derstandings, as well as provide a more nuanced under-
standing of how participants’ different contexts and 
values may affect their decision- making.
Often DCEs rely on visuals to clarify the attributes 
and levels. Pre- piloting with our patient advisory group 
suggested that these are unlikely to be helpful for a popu-
lation living with GA and when conducting the interview 
by telephone. Therefore, we have sought to make the 
text- based option cards as simple and clear as possible. 
An example is shown in figure 3.
Broader questions on the impacts of living with GA
Before concluding the interview, we will use three open- 
ended, semistructured questions inviting participants to 
briefly discuss impacts of GA on their everyday life and 
how these may relate to their hopes for treatment. We 
will conclude by asking participants how they found the 
interview experience, and if they wish to discuss any 
outstanding issues.
Patient involvement
During the study’s conception phase, we convened a group 
of eight individuals living with GA who will be involved 
throughout the study’s entire life cycle. More specifically, 
we have conducted two rounds of involvement activities, 
which have all been conducted remotely (by phone) due 
to COVID-19 restrictions and have helped refine the 
study’s research question and methodology.
During one- to- one discussions with each of the eight 
advisory group members, we explored their knowledge 
and understanding of GA, experiences living with GA 
and their hopes for what treatment might achieve. These 
conversations informed the content and length of the 
structured and semistructured questionnaires, and the 
design of the DCE- style task. We also confirmed with them 
whether they would like to remain engaged in advising 
us throughout the study in the longer term, including 
advising on optimal media to disseminate study results.
Participants
Recruitment
We will use a purposive sampling strategy, aiming to 
achieve maximum variation in our sample,41 in terms 
of demographic characteristics such as age, gender and 
ethnicity, as well as in terms of living situation and grade/
severity of GA. We aim to recruit 30 individuals with GA, 
including 15 participants with a history of previous intra-
vitreal injections (for nAMD) and around 15 participants 
with no experience of intravitreal injections. This will 
help explore whether and how participants’ perspectives 
may differ depending on their experience of previous 
intravitreal injections. We will also ensure that at least five 
participants with fovea- involving GA are included, since 
this could feasibly influence their perspective on the 
acceptability of injections to slow down the progression 
of GA.
Potential participants will be identified from patients 
with GA who attend NHS Medical Retina clinics at Central 
Middlesex Hospital, London. Individuals who may be 
interested and eligible to take part will be approached 
by their consultant ophthalmologist (author CD) or clin-
ical research fellow (author AG), who will explain the 
background, aims and nature of the project. Potential 
participants expressing an interest will then be posted 
a participant information sheet (PIS) in an accessible 
format. After an interval of at least 24 hours to read and 
consider the PIS, authors CD, DJT, AG or JE will contact 
the potential participant to provide an opportunity to 
discuss any queries or uncertainties regarding the study. 
If the participant is willing to proceed, informed verbal 
consent will be obtained by the relevant author. Consent 
will be audio recorded, and the relevant author will record 
this in writing on Qualtrics, with the participant’s permis-
sion. It will be made clear that even having consented, 
the participant is free to withdraw from the study at any 
point without any consequence. Once informed consent 
is obtained, the interview will take place.
Eligibility criteria
We seek to include 15 participants with nAMD in their 
fellow eye and a history of intravitreal injections. For the 
other 15 participants, it will be required that there is no 
history of nAMD or intravitreal injections.
Inclusion criteria across all participants will be as 
follows: age ≥50 years; a diagnosis of GA (bilateral or 
unilateral); and sufficient understanding of and fluency 
in English to be able to understand and respond to inter-
view questions.
Individuals will be excluded in case of macular disease 
in either eye due to causes other than AMD (eg, diabetic 
Figure 3 Example of two of the options to be compared 
and discussed in the discrete choice experiment- style task. 
AMD, age- related macular degeneration.
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macular oedema, Stargardt disease); any concurrent 
ocular or intraocular condition that could contribute to 
central visual impairment; or significant systemic disease 
or medication known to affect central visual function. 
We will also exclude participants if they are unable to 
understand and retain the study information in order to 
provide informed consent.
Sample size
This pilot mixed- methods study can be seen as qualitatively 
driven,42 which is to say that we envisage the qualitative 
component as ‘a complete study that could be published 
alone, but it is complemented with another data set’.43 
For this reason, we have not calculated a sample size or 
prespecified a data saturation point.
In this study, we adopt a realist approach to qualitative 
research, where we assume that participants’ accounts 
are a straightforward, direct reflection of their actual 
thoughts and experiences.44 It is impossible to set a 
theoretical limit in advance for how many interviews will 
provide us with new and meaningful information.45
Therefore, the sample size of 30 was chosen pragmat-
ically to allow a wide range of perspectives to be repre-
sented in the dataset while also being a realistically 
attainable goal. It will allow us to explore the variation 
between, as well as complexities within, participants’ views 
on GA treatment acceptability; particularly contrasting 
those of the ~15 participants with nAMD and a history of 
intravitreal injections, and the ~15 participants with GA 
only who are completely naïve to AMD treatment.
Data analysis (quantitative)
Statistical analysis will largely be descriptive, functioning 
as a complement to the qualitative data. We will carry 
out basic, exploratory analysis to explore any correla-
tions between scores on our novel Likert- type questions, 
EQ- 5D scores and sociodemographic variables. However, 
the small sample size will limit the nature of any prelim-
inary conclusions that can be drawn from the statistical 
analysis.
Data analysis (qualitative)
Recordings of interviews will be transcribed verbatim 
and then analysed using the Framework Method.46 47 
This method of analysis was chosen as it is well suited to 
applied, multidisciplinary health research with relevance 
for policy and practice. A key element of the analytical 
process is generation of a matrix where each row is a 
‘case’ (participant) and each column a ‘code’ (thematic 
concepts or issues). Codes may be developed deductively, 
according to predetermined areas of interest, or induc-
tively, based on open coding of meaningful content in 
participants’ accounts. The matrix provides a practical 
tool for comprehensive, transparent summarising and 
analysis of data that facilitates team- working and joint 
discussion throughout the analytical process. Analysis of 
categories of codes across the whole matrix allows for the 
generation of themes that can encapsulate and explain 
findings. The qualitative software package NVIVO V.10.2 
(QSR International, Cambridge, Massachusetts, USA) 
will be used to manage the matrix framework.
We will use Consolidated criteria for Reporting Qual-
itative research (COREQ)48 as a checklist to encourage 
transparency and reflexivity when writing up our find-
ings, while mindful of critiques that such checklists do not 
necessarily reflect best practice in qualitative research.49
ETHICS AND DISSEMINATION
Ethical considerations
The study received a favourable opinion from the Propor-
tionate Review Subcommittee of the NHS South Central–
Berkshire Research Ethics Committee on 10 March 2021 
(REC reference: 21/SC/0085). Full ethical approval from 
the Health Research Authority was granted on 23 March 
2021 (IRAS Project ID: 287824).
With participants’ consent, telephone interviews will be 
audio recorded and transcribed. All data will be anony-
mised, with all personal data, such as names, addresses, 
dates of birth and so on, being removed. Research data 
will be stored separately from personal identifiable infor-
mation. Identification of research data will be possible 
by investigators by means of a unique alphanumerical 
identifier for each participant. Only investigators will be 
able to identify the participants using the alphanumerical 
identifier.
Anonymised data will be stored electronically for 5 years 
on encrypted, password- protected NHS Trust storage. 
These passwords will only allow access by the researchers.
Any personal data that is transferred electronically will 
be encrypted during transfer. Any hard copies of personal 
data will be stored within the hospital in locked filing 
cabinets.
Dissemination
Participants may opt to receive a summary of the research 
findings at the conclusion of the study. A document will 
be compiled with input from our patient advisory group, 
describing the findings in lay terms. We also hope to 
disseminate findings to patients with GA (beyond patient 
advisors and study participants) through talks and lay 
publications, for example, via support groups run by the 
Macular Society.
Findings will also be disseminated through peer- 
reviewed journal publications and conference presen-
tations. We expect significant interest from the medical 
retina community, and hope that findings will inform 
therapy development and service delivery planning with 
regard to the GA treatments under clinical investigation.
DISCUSSION
Clinical trials of new intravitreal treatments for GA show 
promising results. However, it is unknown whether people 
with GA would accept frequent intravitreal injections for 
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a benefit currently limited to slowing, rather than halting, 
GA progression.
This study represents a first step towards answering that 
question, in a specific context of one GA population in 
London. A key strength of our study is the involvement 
of a patient advisory group who have helped us to shape 
the content and design of our research; however, a limita-
tion is that conducting the study remotely by telephone 
risks missing meaningful non- verbal information, such as 
facial cues and body language.50 While this pilot study will 
not provide a generalisable, definitive answer, we believe 
that results will provide an initial basis for considering 
GA treatment acceptability and the determining factors. 
These barriers and facilitators may be more psychoso-
cial—in terms of hopes or concerns of the patient (and 
their relatives or caregivers, if relevant)—or more attrib-
utable to features of the treatment schedule or the health 
service, such as frequency of treatment or time spent in 
clinic. As such, the study will generate useful insights to 
consider how benefits and risks of treatment can best 
be communicated to patients, while also considering 
if certain treatment options and schedules are clearly 
preferred over others. We also anticipate that the research 
will generate additional insights into the experience of 
living with GA, which can inform broader patient support 
and patient education strategies.
This study will form the basis for a larger quantitative 
study to assess treatment preferences in GA more empir-
ically across a broader range of participants. There are 
existing quantitative measures to assess acceptability used 
in psychosocial research, such as the Treatment Accept-
ability/Adherence Scale51 and the Treatment Perception 
and Preferences measure.52 The Theoretical Framework 
for Acceptability, developed by Sekhon and colleagues, 
is also being used to develop questionnaire items which 
could be applied generically to assess intervention accept-
ability.25 Therefore, our study will help us to consider 
whether these measures may be appropriate for a larger 
study, or how we might construct and validate our own 
questionnaire. To our knowledge, there is no pre- existing, 
validated measure within ophthalmology with which to 
assess treatment acceptability. Instead, acceptability tends 
to be investigated using a combination of qualitative data 
and Likert- type scale questions (as in this pilot study).53 54 
Therefore, we hope that this pilot and the next phase of 
research will not only help to understand empirically how 
patients with GA perceive emerging treatment options, 
but also to further understanding of treatment accept-
ability in ophthalmology more broadly.
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